Your browser doesn't support javascript.
loading
CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
Martens, Anne W J; Janssen, Susanne R; Derks, Ingrid A M; Adams Iii, Homer C; Izhak, Liat; van Kampen, Roel; Tonino, Sanne H; Eldering, Eric; van der Windt, Gerritje J W; Kater, Arnon P.
Afiliação
  • Martens AWJ; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands.
  • Janssen SR; Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Derks IAM; Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Adams Iii HC; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands.
  • Izhak L; Janssen Pharmaceutical Companies of Johnson and Johnson, Philadelphia, Pennsylvania, USA.
  • van Kampen R; Janssen Pharmaceutical Companies of Johnson and Johnson, Philadelphia, Pennsylvania, USA.
  • Tonino SH; Department of Internal Medicine, Zuyderland Medical Centre Heerlen, Heerlen, The Netherlands.
  • Eldering E; Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • van der Windt GJW; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands.
  • Kater AP; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands.
J Immunother Cancer ; 8(1)2020 06.
Article em En | MEDLINE | ID: mdl-32581054
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Sulfonamidas / Ativação Linfocitária / Linfócitos T / Leucemia Linfocítica Crônica de Células B / Complexo CD3 / Anticorpos Biespecíficos / Compostos Bicíclicos Heterocíclicos com Pontes / Antígenos CD19 Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Sulfonamidas / Ativação Linfocitária / Linfócitos T / Leucemia Linfocítica Crônica de Células B / Complexo CD3 / Anticorpos Biespecíficos / Compostos Bicíclicos Heterocíclicos com Pontes / Antígenos CD19 Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2020 Tipo de documento: Article